DRIOMEDIUM SIGNALFINANCIAL10-K

DRIO executed a 20-for-1 reverse stock split while showing improved operational performance with 43% revenue growth and significant reductions in R&D expenses and operating losses.

The reverse stock split from 41.5M to 7.3M shares typically signals management's attempt to boost share price and meet listing requirements, suggesting prior stock price weakness. However, the company is showing operational improvement with substantially reduced cash burn and better cost control, which could indicate a turnaround in progress.

Comparing 2026-03-19 vs 2025-03-10View on EDGAR →
FINANCIAL ANALYSIS

DRIO demonstrated mixed but generally positive financial trends, with revenue growing strongly by 43% to $7.4M while dramatically cutting R&D expenses by 43% to $13.8M. The company significantly improved its cash burn, reducing operating losses by 37% and operating cash flow deficit by 33%, though cash reserves declined to $21.8M. Current liabilities dropped 44% to $9.3M, suggesting better working capital management, and the overall picture indicates a company moving toward operational efficiency despite the reverse stock split signaling previous market challenges.

FINANCIAL STATEMENT CHANGES
Current Liabilities
Balance Sheet
-44%
$16.6M$9.3M

Current liabilities reduced — improved short-term financial position and working capital health.

Revenue
P&L
+43%
$5.2M$7.4M

Strong top-line growth of 43% — accelerating demand or successful expansion into new markets.

R&D Expense
P&L
-43%
$24.2M$13.8M

R&D spending cut 43% — could signal cost discipline or concerning reduction in innovation investment.

Operating Income
P&L
+36.5%
-$57.7M-$36.7M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Operating Cash Flow
Cash Flow
+32.7%
-$38.6M-$25.9M

Operating cash flow surged 32.7% — exceptional cash generation, highest quality earnings signal.

Cash & Equivalents
Balance Sheet
-21.5%
$27.8M$21.8M

Cash decreased 21.5% — monitor burn rate and upcoming capital needs.

Current Assets
Balance Sheet
-13.5%
$40.5M$35.1M

Current assets declined 13.5% — monitor working capital adequacy and short-term liquidity.

LANGUAGE CHANGES
NEW — 2026-03-19
PRIOR — 2025-03-10
ADDED
As of March 1 1, 2026, the registrant had outstanding 7,300,406 shares of common stock, $ 0.0001 par value per share.
Important factors that could cause such differences include, but are not limited to: our current and future capital requirements and our ability to satisfy our capital needs through financing transactions or otherwise; our ability to meet the requirements of our existing debt facility; our product launches and market penetration plans; the execution of agreements with various providers for our solution; our ability to maintain our relationships with key partners; our ability to maintain or protect the validity of our U.S.
and other patents and other intellectual property; our ability to retain key executive members; our ability to internally develop new inventions and intellectual property; general market, political and economic conditions in the countries in which we operate, including those related to recent unrest and actual or potential armed conflict in Israel and other parts of the Middle East; our ability to effectuate a strategic transaction; interpretations of current laws and the passages of future laws; and acceptance of our business model by investors.
Dario is registered as a trademark in the United States, China, Canada, Hong Kong, Australia, Brazil, the EU, and is also registered as a WO (WIPO registration).
DarioHealth is registered as a trademark in the United States, Israel, China, Canada, Australia, India, Japan, the EU, and as a WO.
+7 more — sign up free →
REMOVED
As of March 3, 2025, the registrant had outstanding 41,567,016 shares of common stock, $0.0001 par value per share.
When used in this Annual Report, the terms Dario, DarioHealth, the Company, we, our, and us refer to DarioHealth Corp., a Delaware corporation and our subsidiary LabStyle Innovation Ltd., an Israeli company, PsyInnovations Inc., a Delaware company, Twill, Inc., a Delaware company, Twill ISR Ltd, an Israeli company, and DarioHealth India Services Pvt.
Dario is registered as a trademark in the United States, Israel, China, Canada, Hong Kong, South Africa, Japan, Costa Rica, and Panama.
DarioHealth is registered as a trademark in the United States and Israel.
Business Overview We are a leading global digital health company with a mission to power the behavior changes that drive better health.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →